billS4552Event Monday, May 18, 2026Analyzed

Moms Matter Act

Neutral

Summary

The Moms Matter Act (S.4552) is an early-stage bill authorizing a grant program for maternal mental health and substance use disorder services. It has been referred to committee with no funding appropriated. Market impact is minimal at this procedural stage.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.S.4552 is in early legislative stage with no funding appropriated.
  • 2.Grant program targets maternal mental health but no dollar amount specified.
  • 3.Near-term market impact is negligible; no actionable trades at this stage.

Market Implications

No immediate market implications. The bill is too early-stage and lacks funding to affect any company's financials. Investors should monitor committee action and any subsequent appropriations bills.

Full Analysis

1) On May 18, 2026, Senator Gillibrand introduced S.4552, the Moms Matter Act, which was read twice and referred to the Senate Committee on Health, Education, Labor, and Pensions. The bill is in the earliest legislative stage with no hearings or markup scheduled. 2) The bill authorizes a grant program through HHS to address maternal mental health and substance use disorders, but it does not specify a funding amount. Authorization is not appropriation; actual funding requires a separate appropriations bill. No money has been allocated. 3) Potential beneficiaries include healthcare providers with maternity and behavioral health services, such as hospital systems and managed care organizations with behavioral health divisions ($UNH's Optum). However, the grant program is competitive and not yet funded, so structural winners are not yet identifiable. 4) No real market data is provided for these tickers. The healthcare sector is broad; the bill's focus on maternal health is a niche area within it. 5) The bill must pass committee, be voted on by the Senate, pass the House, and be signed into law. Then appropriations must be passed. This process typically takes multiple sessions; passage in the 119th Congress is uncertain.

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderMay 29, 2026

Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries

This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.